The IMI Ebola+ programme was launched in response to the Ebola virus disease (EVD) outbreak that started in western Africa in 2014. The comprehensive programme contributes to efforts to tackle a wide range of challenges in Ebola research, including vaccines development, clinical trials, storage and transport, as well as diagnostics and treatments.

It is hoped that the programme, which complements work being carried out with the support of other funding bodies, will help to make a difference in the current and future outbreaks. In addition to Ebola, the programme will also address related diseases, such as Marburg. 8 projects, with a total budget of over €200 million, have been selected for funding under the first Ebola+ Call for proposals.

 

Vaccine development projects

  • VSV-EBOVAC
  • EBOVAC 1 and 2

Vaccine manufacture capability projects

  • EBOMAN

Deployment of and compliance with vaccination regimens projects

  • EBODAC

Rapid diagnostic test projects

  • Mofina
  • FILODIAG
  • EbolaMoDRAD

For more information on the other Ebola+ projects:

http://www.imi.europa.eu/content/ebola-programme

News

  • 13 November 2016

    The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.

  • 22 April 2016

    EBOVAC1 has published their first report on Phase 1 data in the April 19th 2016 issue of JAMA

    Press release and more information

  • 04 April 2016

    The first subject was vaccinated on 30 March 2016 at the University of Nairobi, Kenya

  • 29 March 2016

    The 1st EBOVAC2 Newsletter is available!

  • 29 February 2016

    The first subject was randomized on 10 December 2016 at Makerere University in Uganda.

  • 29 February 2016

    The first subject was randomized at CHU Treichville in Côte d'Ivoire on 26 February 2016.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research